Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sonja, Schiffer"'
Publikováno v:
Journal of Thrombosis and Thrombolysis. 55:449-463
Rivaroxaban is a direct, oral factor Xa inhibitor that is used for the prevention and treatment of various thromboembolic disorders. Several preclinical and clinical studies have utilized specific molecules as biomarkers to investigate the potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59ab85d47ea70de234cee463111bd0a4
https://doi.org/10.1007/s11239-023-02776-z
https://doi.org/10.1007/s11239-023-02776-z
Autor:
Paulus Kirchhof, Michael D. Ezekowitz, Yanish Purmah, Sonja Schiffer, Isabelle L. Meng, A. John Camm, Stefan H. Hohnloser, Anke Schulz, Melanie Wosnitza, Riccardo Cappato
Publikováno v:
TH Open, Vol 04, Iss 01, Pp e20-e32 (2020)
Introduction This X-VeRT (eXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion) substudy evaluated the effects of treat
Externí odkaz:
https://doaj.org/article/4684f89640f5438ab6e6f2148ca93bc5
Autor:
Theo Thepen, Stefan Barth, Rainer Fischer, Michael Huhn, Radoslav Mladenov, Eric Aslanian, Dmitrij Hristodorov, Sonja Schiffer
Publikováno v:
Antibodies, Vol 2, Iss 1, Pp 9-18 (2013)
Human cytolytic fusion proteins (hCFPs) are comprised of a specific cell-surface-binding moiety and an effector molecule of human origin. In contrast to common immunotoxins, including bacterial or plant toxins, they are considered not to be immunogen
Externí odkaz:
https://doaj.org/article/c4fc28ca06f54d36aa55e814992f431c
Publikováno v:
Antibodies, Vol 2, Iss 1, Pp 19-49 (2013)
Conventional cancer treatments lack specificity and often cause severe side effects. Targeted therapeutic approaches are therefore preferred, including the use of immunotoxins (ITs) that comprise cell-binding and cell death-inducing components to all
Externí odkaz:
https://doaj.org/article/d91f291eab064c248596b38da70950e6
Autor:
Stephan Schwers, Sigrun Unger, Sonja Schiffer, Ashraf Yassen, Dirk Thomas, Stefanie Kraff, Kirstin Thelen, Stefanie Boxnick
Publikováno v:
Research and Practice in Thrombosis and Haemostasis
Background Coagulation factor XI (FXI) contributes to the development of thrombosis but appears to play only a minor role in hemostasis and is therefore an attractive anticoagulant drug target. Objectives To evaluate the safety, pharmacodynamic, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e27ba5410572585228602e6a12306082
https://doi.org/10.1002/rth2.12186
https://doi.org/10.1002/rth2.12186
Autor:
A. John Camm, Riccardo Cappato, Michael D. Ezekowitz, Stefan H. Hohnloser, Anke Schulz, Isabelle Ling Meng, Melanie Wosnitza, Paulus Kirchhof, Yanish Purmah, Sonja Schiffer
Publikováno v:
TH Open, Vol 04, Iss 01, Pp e20-e32 (2020)
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open: Companion Journal to Thrombosis and Haemostasis
Introduction This X-VeRT (eXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion) substudy evaluated the effects of treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b99d2f762b8eae5471c9b960a00a0382
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1701206
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1701206
Autor:
S H Hohnloser, Ezekowitz, Yanish Purmah, R. Cappato, Paulus Kirchhof, Anke Schulz, Alan John Camm, Melanie Hemmrich, Sonja Schiffer, Isabelle Ling Meng
Publikováno v:
European Heart Journal. 38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2224929b1bca04c4385be940b93d825b
https://doi.org/10.1093/eurheartj/ehx502.p2642
https://doi.org/10.1093/eurheartj/ehx502.p2642
Autor:
Stefan Barth, Edgar Jost, Theo Thepen, Grit Hehmann-Titt, Sonja Schiffer, Georg Melmer, Michael Huhn, Reinhard Rosinke
Publikováno v:
International Journal of Cancer. 135:1497-1508
CMML (chronic myelomonocytic leukemia) belongs to the group of myeloid neoplasms known as myelodysplastic and myeloproliferative diseases. In some patients with a history of CMML, the disease transforms to acute myelomonocytic leukemia (AMML). There
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f1d4ae54898d6f809af10e24dd8d4fd
https://doi.org/10.1002/ijc.28786
https://doi.org/10.1002/ijc.28786
Autor:
Dmitrij Hristodorov, Soriba Letzian, Rainer Fischer, Radoslav Mladenov, Theo Thepen, Edgar Jost, Sonja Schiffer, Michael Huhn, Stefan Barth
Publikováno v:
Cancer Letters. 341:178-185
Immunotoxins are promising targeted therapeutic agents comprising an antibody-based ligand that specifically binds to diseased cells, and a pro-apoptotic protein. Toxic components from bacteria or plants can trigger a neutralizing immune response, so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::523f2511f65a3b02733923f805c213b8
https://doi.org/10.1016/j.canlet.2013.08.005
https://doi.org/10.1016/j.canlet.2013.08.005
Publikováno v:
Antibodies, Vol 2, Iss 1, Pp 19-49 (2013)
Conventional cancer treatments lack specificity and often cause severe side effects. Targeted therapeutic approaches are therefore preferred, including the use of immunotoxins (ITs) that comprise cell-binding and cell death-inducing components to all
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0d15b59b3dff7defbbe162871a719c5
https://doi.org/10.3390/antib2010019
https://doi.org/10.3390/antib2010019